World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

Abstract

These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

“…In addition, experts in specific areas contributed to the relevant sections. The working group considered recent international CPGs, including the UK National Institute for Health and Care Excellence (NICE) (2014) clinical guideline on the treatment and management of psychosis and schizophrenia in adults and the World Federation of Societies of Biological Psychiatry guidelines for the biological treatment of schizophrenia (Hasan et al, 2012(Hasan et al, , 2013(Hasan et al, , 2015Thibaut et al, 2015). The staging model (McGorry et al, 2006) provided a framework for assessment and clinical management and for the choice and timing of interventions.…”

BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment

“…The World Federation of Societies of Biological Psychiatry (WFSBP) has published a guideline on the long-term treatment of schizophrenia and management of antipsychotic-induced adverse effects (Hasan et al, 2013), which includes the management of weight gain and metabolic changes. Their conclusions were similar to those of the Cochrane Review for weight and metabolic measurements with regard to switching from olanzapine to aripiprazole or quetiapine.…”

Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia

“…Schizophrenic patients often require this therapy their entire lives (Miyamoto et al 2005). Unfortunately, antipsychotics also have a spectrum of side effects, including metabolic, endocrine, cardiovascular and movement disorders (Staller 2006;Hasan et al 2012Hasan et al , 2013Lally and MacCabe 2015). Low efficacy of therapy and intolerable side effects are the main causes of non-compliance and discontinuation of treatment in more than 70% of patients with schizophrenia, often resulting in the relapse of psychosis (Miyamoto et al 2005).…”